Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
A Study to Evaluate the Safety and Effectiveness of Novantrone Therapy Followed by Copaxone for Multiple Sclerosis
Uhthoff's phenomena in MS-clinical features and pathophysiology.
Ustekinumab success in refractory Crohn’s disease
Dose comparison trial of sustained-release fampridine in multiple sclerosis.
Brain Volume Loss during the First Year of Interferon-Beta Treatment: Baseline Inflammation and Tissue-Specific Volume Dynamics.
Receptos reports third quarter 2013 financial results
LKB1-regulated adaptive mechanisms are essential for neuronal survival following mitochondrial dysfunction.
Receptos to deliver scientific presentations about RPC1063 at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
Alemtuzumab for the Treatment of Multiple Sclerosis
Acorda Therapeutics announces initiation of AMPYRA® proof-of-concept study in patients with post-stroke deficits
Neuromyelitis optica and pregnancy during therapeutic B cell depletion: infant exposure to anti-AQP4 antibody and prevention of rebound relapses with low-dose rituximab postpartum.
Safety and efficacy of mitoxantrone in pediatric patients with aggressive multiple sclerosis.
Cytokines and adhesion molecules in multiple sclerosis patients treated with interferon-beta1b.
Revimmune (High-Dose Cyclophosphamide) for Autoimmune Diseases
The two faces of neuromyelitis optica.
Glatiramer acetate, an anti-demyelination drug, reduced rats' epileptic seizures induced by pentylenetetrazol via protection of myelin sheath.
EMD Serono
Genzyme Assumes Primary Responsibility for the Development and Commercialization of Alemtuzumab for Multiple Sclerosis; Acquires Bayer’s Hematologic Oncology Portfolio; First of Two Alemtuzumab MS Phase 3 Trials Completes Enrollment
Genzyme's Lemtrada™ Approved in Brazil for Treatment of Multiple Sclerosis
Reduced cerebrospinal fluid concentrations of oxysterols in response to natalizumab treatment of relapsing remitting multiple sclerosis.
Necrotizing skin lesion and radial nerve palsy in a patient treated with glatiramer acetate.
Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study.
Gender identity disorders and multiple sclerosis risk: A national record-linkage study.
Distinction and temporal stability of conformational epitopes on myelin oligodendrocyte glycoprotein recognized by patients with different inflammatory central nervous system diseases.

Pages